Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Xilio Therapeutics ( (XLO) ) has issued an update.

On March 12, 2026, Xilio Therapeutics announced that it would implement a 1-for-14 reverse stock split of its common shares, effective at 5:00 p.m. Eastern Time on March 13, 2026. The move, approved by stockholders at a special meeting on February 23, 2026, is intended to raise the company’s per-share price and help it regain compliance with the Nasdaq Capital Market’s minimum bid price requirements.

Following the reverse split, Xilio’s common stock is expected to begin trading on a split-adjusted basis on March 16, 2026 under the ticker XLO with a new CUSIP, reducing outstanding shares from about 73.5 million to roughly 5.2 million. The action leaves the number of authorized shares and par value unchanged, adjusts related warrants and equity awards, and provides cash in lieu of fractional shares, affecting the capital structure and share count for existing investors without altering underlying ownership proportionally.

The most recent analyst rating on (XLO) stock is a Hold with a $0.59 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.

Spark’s Take on XLO Stock

According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.

The score is primarily held back by weak financial fundamentals (large losses, ongoing cash burn, and negative equity) despite strong recent revenue growth. Technicals are mixed with a weak longer-term trend but neutral-to-stable near-term momentum. Corporate events improve the outlook by extending cash runway into 2027, while valuation is constrained by a negative P/E and no dividend data.

To see Spark’s full report on XLO stock, click here.

More about Xilio Therapeutics

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for people living with cancer. The company leverages proprietary masking technology to create tumor-activated I-O molecules designed to concentrate anti-tumor activity within the tumor microenvironment and improve the therapeutic index versus existing systemic treatments.

Xilio’s pipeline targets patients who require more effective and better-tolerated cancer therapies, positioning the firm within the competitive immuno-oncology space. By pursuing localized activation of immune therapies, the company aims to address safety and efficacy limitations of current I-O drugs and strengthen its standing among biotech peers focused on next-generation cancer treatments.

Average Trading Volume: 436,637

Technical Sentiment Signal: Sell

Current Market Cap: $39.67M

See more insights into XLO stock on TipRanks’ Stock Analysis page.